ResMed (RMD)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-15
$229.44+2.89%
Close 2026-09-15 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-15
Research Workspace
Put RMD beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar broken — Maintain gross margin near 62-63%: FY26 gross margin 61.1% vs 62-63% target; Q4 58.8% vs 60% trip.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthRanks among the strongest in its industry on quality — around the top 10%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskRMD's growth in the sleep device market must continue to justify its current valuation. Revenue grew 9% year over year, and the last quarter beat expectations. It trades at 20× P/E versus a peer median of 28×, indicating that the price reflects less growth than forecasted. A specific risk is the potential for guidance cuts, with a 20% miss probability for the next quarter. Peer multiples imply a price about 7% below where it trades. The thesis has broken due to a primary pillar failing to maintain gross margin near 62-63%.
Trailing returns as of 2026-09-15. RMD is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 19 analysts currently covering RMD (as of Sep 2026).
Based on 9 Wall Street analysts offering 12-month price targets for RMD in the last 4 months.
Continue this research
Compare RMD with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| RMD Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 13 valuation methods, at three horizons. As of 2026-09-15. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put RMD next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Maintain and improve gross margin through cost efficiencies
Rising costs may impact gross margin objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-15. EPS is implied from price ÷ P/E. Not investment advice.
Current $229.44
The last 12 months of price, then the range of analyst 12-month targets from today’s $229.44.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Invest in innovation and scale digital health capabilities
Upgrade reflects confidence in innovation and growth potential.
Advances: Invest in innovation and scale digital health capabilities
Sleep business growth supports innovation and digital health objectives.
Recall impacts outlook and guidance for future performance.
Threatens: Maintain and improve gross margin through cost efficiencies
Margin pressures could hinder cost efficiency objectives.
Threatens: Maintain gross margin guidance
Weak sales forecast raises concerns about future growth.
Advances: Invest in innovation and scale digital health capabilities
Strong growth and strategic M&A align with innovation objectives.
Threatens: Maintain gross margin guidance
GLP-1 concerns may impact gross margin guidance.
